Evidence map›Paper›PMID 28187774›Full record

ArticleHarm reduction journal2017

Assessing the experience of using synthetic cannabinoids by means of interpretative phenomenological analysis.

Szilvia Kassai, Judit Nóra Pintér, József Rácz, Brigitta Böröndi, Tamás Tóth-Karikó, Kitti Kerekes, V Anna Gyarmathy

Open access · goldAbstract read
In one paragraph

Article in Harm reduction journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Szilvia KassaiDoctoral School of Psychology, Eötvös Loránd University, Budapest, Hungary. kassai.szilvia@ppk.elte.hu.
Judit Nóra PintérInstitute of Psychology, University of Szeged, Szeged, Hungary.
József RáczInstitute of Psychology, Eötvös Loránd University, Budapest, Hungary.
Brigitta BöröndiFaculty of Health Sciences, Semmelweis University, Budapest, Hungary.
Tamás Tóth-KarikóFaculty of Health Sciences, Semmelweis University, Budapest, Hungary.
Kitti KerekesFaculty of Health Sciences, Semmelweis University, Budapest, Hungary.
V Anna GyarmathyFaculty of Health Sciences, Semmelweis University, Budapest, Hungary.
Semmelweis University · HUEötvös Loránd University · HUUniversity of Szeged · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNew psychoactive substances (NPS) have been increasingly consumed by people who use drugs in recent years, which pose a new challenge for treatment services. One of the largest groups of NPS is synthetic cannabinoids (SCs), which are intended as a replacement to cannabis. While there is an increasing body of research on the motivation and the effects associated with SC use, little is known about the subjective interpretation of SC use by the people who use drugs themselves. The aim of this study was to examine the experiences and personal interpretations of SC use of users who were heavily dependent on SC and are in treatment.

methodsA qualitative research method was applied in order to explore unknown and personal aspects of SC use. Semi-structured interviews were conducted with six participants who had problematic SC use and entered treatment. The research was conducted in Hungary in 2015. We analyzed data using interpretative phenomenological analysis (IPA).

resultsParticipants perceived SCs to be unpredictable: their initial positive experiences quickly turned negative. They also reported that SCs took over their lives both interpersonally and intrapersonally: the drug took their old friends away, and while initially it gave them new ones, in the end it not only made them asocial but the drug became their only friend, it hijacked their personalities and made them addicted.

conclusionsParticipants experienced rapid development of effects and they had difficulties interpreting or integrating these experiences. The rapid alteration of effects and experiences may explain the severe psychopathological symptoms, which may be important information for harm reduction and treatment services. Since, these experiences are mostly unknown and unpredictable for people who use SCs, a forum where they could share their experiences could have a harm reducing role. For a harm reduction point of view of SCs, which are underrepresented in literature, it is important to emphasize the impossibility of knowing the quantity, purity, or even the number of different SC compounds in a particular SC product. Our study findings suggest that despite the adverse effects, including a rapid turn of experiences to negative, rapid development of addiction and withdrawal symptoms of SCs, participants continued using the drug because this drug was mostly available and cheap. Therefore, a harm reduction approach would be to make available and legal certain drugs that have less adverse effects and could cause less serious dependence and withdrawal symptoms, with controlled production and distribution (similarly to cannabis legalization in the Netherlands).

Indexed as

Designer DrugsAdultCannabinoidsHarm ReductionHumansHungaryInterviews as TopicMaleMarijuana AbuseYoung AdultCannabinoidsDesigner DrugsHarm reductionInterpretative phenomenological analysisNew psychoactive substancesQualitative studySynthetic cannabinoidsUser experience

Identifiers

PMID28187774
PMCPMC5303230
OpenAlexW2586090219

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.